晚期NSCLC中循环肿瘤DNA水平的基因型特异性差异
该回顾性研究分析144例晚期NSCLC患者的ctDNA与组织基因组数据及影像,发现ctDNA变异等位基因频率与肿瘤负荷呈中度显著相关,且相关性因基因型而异:KRAS突变最强、EGFR突变最弱;TP53和EGFR突变、内脏转移及肿瘤负荷是ctDNA释放增加的独立预测因素。
要点
- ctDNA水平不仅受肿瘤负荷影响,还受肿瘤基因型影响
- KRAS突变者ctDNA与肿瘤负荷相关性最强,EGFR突变者最弱
- EGFR拷贝数增益的EGFR突变肿瘤ctDNA水平显著更高
核心结论
- 可检测的ctDNA水平受肿瘤负荷和肿瘤基因型共同影响,基因型差异可能源于DNA释放和细胞周转的不同。
研究设计与样本
- 回顾性分析144例NSCLC患者的ctDNA基因组、组织基因组和影像数据,总体队列用CT和脑MRI量化肿瘤负荷,部分患者用18F-FDG PET-CT。
主要发现
- ctDNA变异等位基因频率与CT体积(rho=0.34,p≤0.0001)和代谢肿瘤体积(rho=0.36,p=0.003)呈中度显著相关。
- 相关性在KRAS突变肿瘤最强(rho=0.56,p≤0.001),TP53突变次之(rho=0.43,p≤0.0001),EGFR突变最弱(rho=0.24,p=0.077)。
- EGFR拷贝数增益的EGFR突变肿瘤变异等位基因频率显著高于无拷贝数增益者(p≤0.00001)。
- 多变量分析中,TP53和EGFR突变、内脏转移及肿瘤负荷是ctDNA释放增加的独立预测因素。
临床怎么用
- 在NSCLC疾病监测和早期检测中应用ctDNA时,需考虑基因型对ctDNA释放水平的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Plasma-based circulating tumor DNA (ctDNA) is an established biomarker for molecular profiling with emerging applications in disease monitoring in multiple tumor types, including, NSCLC. However, determinants of ctDNA shedding and correlation with tumor burden are incompletely understood, particularly in advanced-stage disease. METHODS: We retrospectively analyzed ctDNA-based and tissue-based genomic data and imaging from 144 patients with NSCLC. Tumor burden was quantified with computed tomography (CT) and brain magnetic resonance imaging for the overall cohort and 18F-fludeoxyglucose positron emission tomography-CT in a subset of patients. RESULTS: There was a moderate but statistically significant correlation between ctDNA variant allele frequency and multiple imaging measures of tumor burden such as CT volume (rho = 0.34, p ≤ 0.0001) and metabolic tumor volume (rho = 0.36, p = 0.003). This correlation was strongest in KRAS-mutant tumors (rho = 0.56, p ≤ 0.001), followed by TP53 mutants (rho = 0.43, p ≤ 0.0001), and weakest in EGFR-mutated (EGFR+) tumors (rho = 0.24, p = 0.077). EGFR+ tumors with EGFR copy number gain had significantly higher variant allele frequency than EGFR+ without copy number gain (p ≤ 0.00001). In multivariable analysis, TP53 and EGFR mutations, visceral metastasis, and tumor burden were independent predictors of increased ctDNA shedding. CONCLUSIONS: Levels of detectable ctDNA were affected not only by tumor burden but also by tumor genotype. The genotype-specific differences observed may be due to variations in DNA shedding and cellular turnover. These findings have implications for the emerging use of ctDNA in NSCLC disease monitoring and early detection.
引用
- Lam VK, Zhang J, Wu CC, et al. Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. J Thorac Oncol. 2020. PMID: 33388476. doi:10.1016/j.jtho.2020.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。